Asthika Goonewardene
Stock Analyst at Truist Securities
(2.07)
# 2,978
Out of 5,157 analysts
89
Total ratings
40.7%
Success rate
-6.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Downgrades: Hold | $134 → $120 | $114.39 | +4.90% | 6 | Feb 24, 2026 | |
| ZYME Zymeworks | Initiates: Buy | $40 | $25.46 | +57.11% | 1 | Dec 17, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $43 | $25.33 | +69.76% | 1 | Nov 25, 2025 | |
| GMAB Genmab | Reiterates: Buy | $49 → $48 | $27.96 | +71.67% | 16 | Nov 7, 2025 | |
| GILD Gilead Sciences | Reiterates: Buy | $127 → $145 | $148.56 | -2.40% | 3 | Nov 3, 2025 | |
| RCUS Arcus Biosciences | Reiterates: Buy | $32 → $39 | $24.56 | +58.79% | 2 | Oct 7, 2025 | |
| JANX Janux Therapeutics | Initiates: Buy | $100 | $14.07 | +610.73% | 1 | Sep 10, 2025 | |
| RVMD Revolution Medicines | Initiates: Buy | $99 | $98.86 | +0.14% | 1 | Sep 5, 2025 | |
| EXEL Exelixis | Maintains: Buy | $56 → $49 | $41.29 | +18.67% | 11 | Jul 29, 2025 | |
| BNTX BioNTech SE | Reiterates: Buy | $151 → $155 | $83.89 | +84.77% | 3 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $88 → $71 | $19.56 | +262.99% | 2 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $10 | $2.71 | +269.00% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $10 | $1.60 | +525.00% | 4 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $15 | $5.20 | +188.46% | 6 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $16.33 | +114.33% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $150 | $25.43 | +489.85% | 6 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $2.24 | +78.57% | 5 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 | $2.03 | +835.96% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $432 | $7.53 | +5,637.05% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Hold | $120 | $8.93 | +1,243.78% | 1 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $100 → $60 | $1.39 | +4,216.55% | 3 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $228 → $180 | $12.71 | +1,316.21% | 4 | Aug 23, 2022 |
Arcellx
Feb 24, 2026
Downgrades: Hold
Price Target: $134 → $120
Current: $114.39
Upside: +4.90%
Zymeworks
Dec 17, 2025
Initiates: Buy
Price Target: $40
Current: $25.46
Upside: +57.11%
ArriVent BioPharma
Nov 25, 2025
Initiates: Buy
Price Target: $43
Current: $25.33
Upside: +69.76%
Genmab
Nov 7, 2025
Reiterates: Buy
Price Target: $49 → $48
Current: $27.96
Upside: +71.67%
Gilead Sciences
Nov 3, 2025
Reiterates: Buy
Price Target: $127 → $145
Current: $148.56
Upside: -2.40%
Arcus Biosciences
Oct 7, 2025
Reiterates: Buy
Price Target: $32 → $39
Current: $24.56
Upside: +58.79%
Janux Therapeutics
Sep 10, 2025
Initiates: Buy
Price Target: $100
Current: $14.07
Upside: +610.73%
Revolution Medicines
Sep 5, 2025
Initiates: Buy
Price Target: $99
Current: $98.86
Upside: +0.14%
Exelixis
Jul 29, 2025
Maintains: Buy
Price Target: $56 → $49
Current: $41.29
Upside: +18.67%
BioNTech SE
Jun 3, 2025
Reiterates: Buy
Price Target: $151 → $155
Current: $83.89
Upside: +84.77%
May 14, 2025
Maintains: Buy
Price Target: $88 → $71
Current: $19.56
Upside: +262.99%
May 14, 2025
Maintains: Buy
Price Target: $14 → $10
Current: $2.71
Upside: +269.00%
Apr 1, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $1.60
Upside: +525.00%
Mar 3, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $5.20
Upside: +188.46%
Jan 8, 2025
Initiates: Buy
Price Target: $35
Current: $16.33
Upside: +114.33%
Aug 16, 2024
Maintains: Buy
Price Target: $180 → $150
Current: $25.43
Upside: +489.85%
May 21, 2024
Maintains: Buy
Price Target: $5 → $4
Current: $2.24
Upside: +78.57%
May 16, 2024
Maintains: Buy
Price Target: $19
Current: $2.03
Upside: +835.96%
Sep 6, 2023
Reiterates: Buy
Price Target: $432
Current: $7.53
Upside: +5,637.05%
Apr 5, 2023
Reinstates: Hold
Price Target: $120
Current: $8.93
Upside: +1,243.78%
Aug 23, 2022
Maintains: Hold
Price Target: $100 → $60
Current: $1.39
Upside: +4,216.55%
Aug 23, 2022
Maintains: Buy
Price Target: $228 → $180
Current: $12.71
Upside: +1,316.21%